手术切除囊性肿块效果甚佳， 无手术后死亡的报道。但25%病人术后局部复发。Van der Klooster
等报告1例多发性囊性间皮瘤病人，经抽吸和闭塞治疗均无效，1年内肿瘤复发5次，最后改用经阴道插管
持续引流，终将之治愈。手术切除囊性肿块效果甚佳，无手术后死亡的报道。但25%病人术后局部复发。
目前经腹腔镜也能完整切除巨大腹腔囊性间皮瘤。
Surgical excision of cystic mass effect is very good and without postoperative deaths reported. But 25% of patients with local recurrence. Van der Klooster reports on one cases with multiple cystic mesothelioma patients. by suction and occlusion treatment were ineffective, a tumor recurrence five years times, the last to switch to vaginal intubation continuous drainage, eventually cure. Surgical excision of cystic mass effect is very good and without postoperative deaths reported. But 25% of patients with local recurrence. With laparoscopy can complete resection of giant cystic peritoneal mesothelioma.
恶性间皮瘤 Malignant Mesothelioma
手术疗法 Surgical therapy
对I、Ⅱ期PMM首选手术治疗。术式包括减瘤手术(cytoreductive surgery)，尽可能切除所能见到的
肿瘤组织。但事实上因手术难度大，病变弥漫，难以达到完全切除的目的。对复发者可再次手术。对肠
梗阻者可行姑息性手术，缓解梗阻症状。
Right I, Phase II analyzing the preferred surgical treatment. Operation include the reduction of tumor surgery (cytoreductive surgery), possible removal can see the tumor tissue. But because of the difficulty in surgery, diffuse lesions, the complete resection difficult to achieve the objective. Right recurrence can be re-operation. Ileus is feasible right palliative surgery, obstructive symptoms.
放射疗法 Radiotherapy
PMM对放疗欠敏感，放疗效果不如胸膜间皮瘤。 但对手术未能完全切除病灶或无法手术者，放疗仍不
失为一种重要疗法。方法包括外照射和(或)内照射。外照射一般选用60Co或186KV X线作为放射源，视病
变范围选择全腹或局部照射。 上医大肿瘤医院给病人全腹照射，6～7周内照射剂量达24戈瑞(Gy)，结果
局部复发率降至11.4%，3年生存率提高至66.7%。放疗可引起放射性肠炎、放射性脊髓炎和放射性肝炎等。
腹腔内注射核素如32P或198Au，通过内放射，使间皮瘤组织和小血管硬化，并杀伤腹水中的游离瘤细胞，
使病情获得短期缓解。但此法需一定设备，且代价不菲，并可抑制骨髓，现已少用。
SILVER less sensitive to radiotherapy, radiotherapy result is not as good as pleural mesothelioma. But the surgical resection of the lesions has not been fully or not surgery, radiotherapy is nonetheless an important therapy. Including external irradiation and (or) irradiation. External irradiation generally choose 60 or 186KV Co. as X-ray sources, depending on the scope of diseases to choose partial or whole abdominal irradiation. Medicine tumor patients to the hospital whole abdominal irradiation, six-seven weeks of radiation doses up to 24 gray (Gy). Results of local recurrence rate to 11.4%, three-year survival rate increased to 66.7%. Radiotherapy can cause abdominal radiation, radioactive radiation myelitis and hepatitis. Intraperitoneal injection of radionuclide P as 32 or 198 Au, through radiation and mesothelioma organizations and small vascular sclerosis. and the anti-free ascites tumor cells, a short-term illness mitigation. But this method will need equipment, and the price is very expensive, and can inhibit the bone marrow, has been seldom used.
化学疗法 Chemotherapy
药物 PMM对化疗中度敏感.术前诱导化疗、术中和术后辅助化疗可明显减少肿瘤复发,提高3年存活率。
Drug analyzing moderately sensitive to chemotherapy. Pre-operative chemotherapy, surgery and post-operative adjuvant chemotherapy can significantly reduce tumor recurrence, three years to improve the survival rate.
治疗PMM效果肯定的化学药物有阿霉素、顺氯氨铂、卡铂、博莱霉素及国产抗癌新药榄香烯乳等。长
春新碱、氟脲嘧啶、环磷酰胺、丝裂霉素等也值得一试。
治疗PMM效果肯定的化学药物有阿霉素、顺氯氨铂、卡铂、博莱霉素及国产抗癌新药榄香烯乳等。长
春新碱、氟脲嘧啶、环磷酰胺、丝裂霉素等也值得一试。
SILVER certainly result in the treatment of chemical drugs doxorubicin, cisplatin and carboplatin, bleomycin and a new anticancer drug Eiemene other. Vincristine, fluorouracil, cyclophosphamide, mitomycin also worth a try.
阿霉素(Adriamycin, ADM) 成人每次30～60mg/m2，每3周1次，静脉或腹腔注射，总剂量不超过
550mg/m2。不良反应以心脏毒性为著,且有积聚性,与总剂量有关;其次为抑制骨髓、胃肠道反应及脱发等。
Doxorubicin (Adriamycin, ADM) for each adult 30 ~ routinely. Every three weeks one time, intravenous or intraperitoneal injection of a total dose of not more than 550mg/m2. Adverse reaction to a cardiac toxicity, there is accumulation, with the total dose; Followed by bone marrow suppression. gastrointestinal reactions and alopecia.
顺氯氨铂(Cisplatin, DDP, 顺铂) 成人每次80～120mg/m2，每3周1次；或20mg/m2，连用5天，每3周
为一疗程，静脉注射。不良反应有肾毒性、耳毒性、神经毒性、胃肠道反应和抑制骨髓等。加用甘露醇可
减少其在肾小管中积聚。该药也常用于腹腔内注射，具体方法见下文。
顺氯氨铂(Cisplatin, DDP, 顺铂) 成人每次80～120mg/m2，每3周1次；或20mg/m2，连用5天，每3周
为一疗程，静脉注射。不良反应有肾毒性、耳毒性、神经毒性、胃肠道反应和抑制骨髓等。加用甘露醇可
减少其在肾小管中积聚。该药也常用于腹腔内注射，具体方法见下文。
PDD (cisplatin, DDP, cisplatin) for each adult 80 ~ 120mg/m2, every three times a week; or 20 mg/m2 for 5 days every 3 weeks for a course of treatment, intravenous injection. Adverse reactions are nephrotoxicity and ototoxicity, neurotoxicity, gastrointestinal reactions and bone marrow suppression. Plus mannitol to reduce its accumulated in the tubular cells. The drug is commonly used in the intraperitoneal injection, the specific method described below.
卡铂(Carboplatin, CBP) 成人每次300～400mg/m2，加入5%葡萄糖溶液或生理盐水中，稀释为浓度
0.5mg/ml的溶液，静脉滴注，每3～4周重复；或100mg/d，加入5%葡萄糖溶液500ml中静脉滴注，连用5天；
3～4周重复1次。也可每次用300～500mg腹腔内注射，每周1次。
卡铂(Carboplatin, CBP) 成人每次300～400mg/m2，加入5%葡萄糖溶液或生理盐水中，稀释为浓度
0.5mg/ml的溶液，静脉滴注，每3～4周重复；或100mg/d，加入5%葡萄糖溶液500ml中静脉滴注，连用5天；
3～4周重复1次。也可每次用300～500mg腹腔内注射，每周1次。
Carboplatin (Carboplatin, CBP) Adult 300 ~ 400mg/m2 each. by adding 5% glucose solution or saline, diluting the concentration of the solution 0.5mg/ml, intravenous drip, Each three-four weeks duplication; or 100 mg / d, to 5% glucose solution 500ml intravenous drip for 5 days; 3 ~ 4 times a week to repeat. Can be used for each 300 ~ 500 mg intraperitoneal injection once a week.
博莱霉素(Bleomycin, BLM) 成人用15～30mg，溶于适量生理盐水或5%葡萄糖溶液中深部肌注、静注
或静脉滴注，每周2次；也可根据情况改为1次/d或每周数次。还可用60mg溶解后缓慢注入腹腔。Stey用BLM
腹腔内注射，治疗1例PMM病人，结果腹水消失，停药后未再出现，存活已逾3年。但大剂量BLM腹腔内注射
可引起肺炎样症状，甚至肺纤维化；此外，发热、胃肠道反应较常见，个别病人发生变态反应。
Bleomycin (hopefully, the BLM) Adult use 15 ~ 30mg, dissolved in saline or modest 5% glucose solution deep intramuscular, or intravenous injection two times a week; also, under the circumstances, to a time / d or several times a week. Can also be dissolved after 60 mg intraperitoneal injection of slow. Stey with BLM intraperitoneal injection, treatment one cases analyzing patient outcome ascites disappeared, the withdrawal did not arise again. survived for more than three years. But BLM large dose intraperitoneal injection can cause pneumonia-like symptoms, or even pulmonary fibrosis; In addition, fever, gastrointestinal reactions more common. Patients allergic individual.
紫杉醇（Paclitaxel） 本品是从红豆杉树皮中提取的抗癌药，通过诱导和促进微管蛋白聚合，防止解
聚和稳定微管，抑制了细胞有丝分裂和增殖。紫杉醇还能抑制有丝分裂所需的微管网再生，妨碍有丝分裂
纺锤体的形成导致染色体的断裂，抑制了肿瘤细胞的复制。剂量为135～175 mg/m2，稀释于生理盐水或5%
葡萄糖溶液中静脉注射。每3周重复。用药前12小时应给予地塞米松20 mg，30～60分钟前应静注苯海拉明
50 mg和西米替丁300 mg或雷尼替丁200 mg，以防过敏反应。与顺铂合用对约66.7%的病人有效，并能耐受
其毒性反应[6]。不良反应有抑制骨髓、过敏反应、关节痛、肌痛、胃肠道反应、周围神经病变、昏厥、共
济失调及注射部位肿痛等。
紫杉醇（Paclitaxel） 本品是从红豆杉树皮中提取的抗癌药，通过诱导和促进微管蛋白聚合，防止解
聚和稳定微管，抑制了细胞有丝分裂和增殖。紫杉醇还能抑制有丝分裂所需的微管网再生，妨碍有丝分裂
纺锤体的形成导致染色体的断裂，抑制了肿瘤细胞的复制。剂量为135～175 mg/m2，稀释于生理盐水或5%
葡萄糖溶液中静脉注射。每3周重复。用药前12小时应给予地塞米松20 mg，30～60分钟前应静注苯海拉明
50 mg和西米替丁300 mg或雷尼替丁200 mg，以防过敏反应。与顺铂合用对约66.7%的病人有效，并能耐受
其毒性反应[6]。不良反应有抑制骨髓、过敏反应、关节痛、肌痛、胃肠道反应、周围神经病变、昏厥、共
济失调及注射部位肿痛等。
Taxol (paclitaxel) to be from the yew bark extract anticancer drug induce and promote tubulin polymerization and depolymerization and prevent stable microtubules, inhibit cell proliferation and mitosis. Taxol can inhibit mitosis of the microtubule network renewable, prevent mitotic spindle lead to the formation of chromosome break, inhibit the replication of tumor cells. Dose of 135 ~ 175 mg/m2, diluted in normal saline or 5% glucose solution was injected into the vein. Repeated every 3 weeks. 12 hours before the treatment should be given dexamethasone 20 mg, 30 ~ 60 minutes before intravenous diphenhydramine 50 mg and cimetidine 300 mg or 200 mg of ranitidine. to prevent allergic reactions. And cisplatin combination of about 66.7% of the patients effectively, and the ability under toxicity [6]. Adverse reactions inhibit bone marrow, allergies, joint pain, muscle pain, gastrointestinal reactions, peripheral neuropathy, syncope, Ataxia and the injection site pain and so on.
榄香烯乳(Elemene) 为中药莪术中提取到的抗癌活性物质；胸、腹腔内灌注治疗恶性胸、腹水有较好
疗效。在尽量抽除腹水后，按200～400mg/m2用量注入腹腔，每周1～2次。不良反应发生率为20%～70%，主
要有发热、畏寒和局部疼痛;如预先注入少量麻醉药和激素，则能预防之;其他有过敏反应、胃肠道反应等。
Eiemene (Elemene) curcuma extract of the anticancer activity of substances; Chest, intraperitoneal infusion treatment of malignant thoracic, ascites has a good effect. In addition to pumping as much as possible in ascites, according to 200 ~ 400mg/m2 intraperitoneal injection dosage, the weekly one-two times. Adverse reaction rate of 20% ~ 70%, mainly fever, chills and pain; If pre-anesthetic and inject a small amount of hormones, it will Prevention; other allergic reactions, gastrointestinal reactions.
环磷酰胺(CTX) 成人每次600～1200mg，每周1～2次， 静脉注射。用药后抑制骨髓、胃肠道反应
及出血性膀胱炎等不良反应均较常见。
环磷酰胺(CTX) 成人每次600～1200mg，每周1～2次， 静脉注射。用药后抑制骨髓、胃肠道反应
及出血性膀胱炎等不良反应均较常见。
Cyclophosphamide (CTX) for each adult-1200mg 600, the weekly one-2nd, intravenous. After administration of bone marrow suppression, gastrointestinal reactions and stopped the bleeding bladder are more common adverse reactions.
长春新碱(VCR) 成人每次2.5～8mg/m2，每周1次，静脉注射 ，总量为60～80mg，主要不良反应
为抑制骨髓。
长春新碱(VCR) 成人每次2.5～8mg/m2，每周1次，静脉注射 ，总量为60～80mg，主要不良反应
为抑制骨髓。
Vincristine (VCR) for each adult 2.5 ~ 8mg/m2, a weekly meeting, intravenous, The total amount of 60-80mg, the main adverse reaction to the suppression of bone marrow.
甲氨喋呤(MTX) 成人每次15～50mg，每周1～2次，肌肉或静脉注射。副作用有骨髓抑制、胃肠道反应、
口腔炎、肝肾功能损害等，长期用药可致肺纤维化。
甲氨喋呤(MTX) 成人每次15～50mg，每周1～2次，肌肉或静脉注射。副作用有骨髓抑制、胃肠道反应、
口腔炎、肝肾功能损害等，长期用药可致肺纤维化。
Methotrexate (MTX) for each adult 15-50mg, a weekly two-time, muscle or intravenous injection. Side effects are bone marrow suppression, gastrointestinal reactions, stomatitis, liver and kidney dysfunction, long-term medication can be induced pulmonary fibrosis.
化疗方法 有以下两种。
化疗方法 有以下两种。
Chemotherapy following two methods.
全身化疗 全身给予抗癌药后，腹膜腔内药物分布较少。国外报告，无论单药或联合用药，全身化疗有
效率仅11％～14%。 联合化疗方案包括：DDP+ADM，DDP+CTX+VCR，CTX+VCR+BLM等。但不少学者强调，联合
化疗并不能提高疗效[11]。 Poulain等[12]体外研究了DDP、CBP和两性霉素B(AmB)对恶性间皮瘤细胞株的细
胞毒性作用。给细胞株接触上述药物2小时，6天后得到的生长—抑制曲线表明，浓度为5～10mg/L的AmB对敏
感的或耐药的细胞株，都可使DDP和CBP的50%生长—抑制浓度(IC50)降低5～10倍。 AmB的作用可能与其显著
增加了肿瘤细胞对铂的摄入，提高了细胞内铂的浓度，增强了铂的细胞毒性作用有关。磷酸二酯酶抑制性甲
基黄嘌呤(phosphodiesterase inhibiting methylxanthines) 与AmB有协同作用，其本身毒性弱，且能缓解
AmB的肾毒性。 但迄今未见临床联合应用上述药物的报告。
全身化疗 全身给予抗癌药后，腹膜腔内药物分布较少。国外报告，无论单药或联合用药，全身化疗有
效率仅11％～14%。 联合化疗方案包括：DDP+ADM，DDP+CTX+VCR，CTX+VCR+BLM等。但不少学者强调，联合
化疗并不能提高疗效[11]。 Poulain等[12]体外研究了DDP、CBP和两性霉素B(AmB)对恶性间皮瘤细胞株的细
胞毒性作用。给细胞株接触上述药物2小时，6天后得到的生长—抑制曲线表明，浓度为5～10mg/L的AmB对敏
感的或耐药的细胞株，都可使DDP和CBP的50%生长—抑制浓度(IC50)降低5～10倍。 AmB的作用可能与其显著
增加了肿瘤细胞对铂的摄入，提高了细胞内铂的浓度，增强了铂的细胞毒性作用有关。磷酸二酯酶抑制性甲
基黄嘌呤(phosphodiesterase inhibiting methylxanthines) 与AmB有协同作用，其本身毒性弱，且能缓解
AmB的肾毒性。 但迄今未见临床联合应用上述药物的报告。
Systemic chemotherapy for systemic anticancer drugs, drug distribution peritoneal cavity less. Abroad, whether single or combined drug treatment, chemotherapy efficient only 11% ~ 14%. Combined chemotherapy include : ADM + DDP, DDP + CTX + VCR, CTX VCR + + BLM etc.. But many scholars stressed that the combined chemotherapy and would not improve efficacy [11]. Poulain, etc. [12] In vitro studies of the DDP, CBP and amphotericin B (mg) of malignant mesothelioma cells in vitro. Access to the cells of these drugs two hours, six days after the growth-inhibition curve, concentration of 5 ~ 10 mg / L mg of sensitive or resistant cell line, DDP can enable CBP and the 50% growth-inhibitory concentration (IC50) to reduce 5 ~ 10 times. Mg role may increase significantly with a pair of platinum tumor cell uptake and improve the intracellular concentration of platinum, enhance the cytotoxicity of cisplatin in the role. Phosphodiesterase inhibition methylxanthine (phosphodiesterase inhibitin g methylxanthines) mg a synergistic effect, its own weak toxicity, able to ease mg of renal toxicity. But so far no clinical drug combination of the above report.
腹腔内化疗 近年认为， 腹腔内注射用药可提高局部药物浓度，减轻全身不良反应；不仅能消灭手术
后残留的肿瘤组织，减少复发；还可使部分失却手术机会的病人肿块缩小，腹水减少，病情得到有效控制。
腹腔内用药剂量与静脉一次用量相似，或略高于后者；１周后重复。根据病情可连续注射数周。Ito[13]等
给1例手术未能切除的PMM 病人腹腔注射DDP， 并联合应用了 尿嘧啶 和tegafur，取得了意想不到的效果:
在术后223天腹块和腹水完全消失。但在第8个月后盆腔肿块复发；重新给予DDP和喜树碱，效果却不佳。
Ｍa等[14]则用加温持续腹腔灌注 ( continuous hyperthermic peritoneal perfusion, CHPP)联合DDP
局部注射，治疗PPM。 灌注初始DDP平均量为120mg/ml(81～166mg/ml),灌注流量1.5L/min，平均灌注量为
5.1L(4～7L），灌注90分钟后， 测量腹腔内三处温度分别为41.5℃、40.5℃和41.1℃。灌注液总DDP曲线
下面积(AUC)为血浆DDP AUC的21倍，血浆DDP浓度则与全身用药时相仿。治疗过程中无明显局部不良反应，
病人均能耐受CHPP。随访10个月，无1例因CHPP治疗而死亡。Park 等[15]也有类似的报道。目前看来，
CHPP不啻为治疗PMM的一个有效方法。
腹腔内化疗 近年认为， 腹腔内注射用药可提高局部药物浓度，减轻全身不良反应；不仅能消灭手术
后残留的肿瘤组织，减少复发；还可使部分失却手术机会的病人肿块缩小，腹水减少，病情得到有效控制。
腹腔内用药剂量与静脉一次用量相似，或略高于后者；１周后重复。根据病情可连续注射数周。Ito[13]等
给1例手术未能切除的PMM 病人腹腔注射DDP， 并联合应用了 尿嘧啶 和tegafur，取得了意想不到的效果:
在术后223天腹块和腹水完全消失。但在第8个月后盆腔肿块复发；重新给予DDP和喜树碱，效果却不佳。
Ｍa等[14]则用加温持续腹腔灌注 ( continuous hyperthermic peritoneal perfusion, CHPP)联合DDP
局部注射，治疗PPM。 灌注初始DDP平均量为120mg/ml(81～166mg/ml),灌注流量1.5L/min，平均灌注量为
5.1L(4～7L），灌注90分钟后， 测量腹腔内三处温度分别为41.5℃、40.5℃和41.1℃。灌注液总DDP曲线
下面积(AUC)为血浆DDP AUC的21倍，血浆DDP浓度则与全身用药时相仿。治疗过程中无明显局部不良反应，
病人均能耐受CHPP。随访10个月，无1例因CHPP治疗而死亡。Park 等[15]也有类似的报道。目前看来，
CHPP不啻为治疗PMM的一个有效方法。
Intraperitoneal chemotherapy in recent years that the intraperitoneal injection of medication may improve the local drug concentration and reduce systemic adverse reactions; not only can eliminate postoperative residual tumor tissue, reduce relapse; may lose some of the surgical patients mass reduced, ascites, the condition was under control. Intraperitoneal and intravenous dose of a similar amount, or slightly higher than the latter; A week later to repeat. Under the condition can be continuous injection of a few weeks. Ito [13], so as to not one cases surgical resection of analyzing patients intraperitoneal injection of DDP, and the combination of uracil and tegafur, made unexpected effect : 223 days after the abdominal mass and ascites completely disappear. But in the first eight months after pelvic tumor recurrence; Restore DDP and camptothecin, the result is poor. Ma, and so on [14] used a continuous warming peritoneal perfusion (continuous hyperthermic peritoneal perfusion, CHPP) combined with cisplatin injection. PPM treatment. DDP initial perfusion average volume of 120 mg / ml (~ 81 166mg/ml), .5L/min a perfusion flow rate, the average amount of reperfusion 5.1L (4-7L), 90 minutes after reperfusion. Measurement intraperitoneal three temperature of 41.5 ° C, 40.5 ° C and 41.1 ° C. Perfused with DDP total area under the curve (AUC) for plasma AUC DDP 21 times, DDP plasma concentration and systemic medication when similar. The course of treatment no local adverse reactions, patients were able to tolerance CHPP. Follow-up of 10 months, no cases of death CHPP treatment. Park and so on [15] also have similar reports. Currently, the CHPP analyzing the results of the treatment of one of the effective ways.
生物反应修饰疗法 Bioreactor modification therapy
生物反应修饰剂(biological response modifier, BRM) 是体内自身的一些细胞和分子，能应答机
体对内外环境的刺激，并参与维持机体内环境的稳定。BRM通过调动机体固有能力抵御和消灭肿瘤，成为当
今治疗肿瘤的新模式。随着细胞工程和基因工程的进展，BRM在肿瘤治疗领域大有用武之地。
生物反应修饰疗法 Bioreactor modification therapy
生物反应修饰剂(biological response modifier, BRM) 是体内自身的一些细胞和分子，能应答机
体对内外环境的刺激，并参与维持机体内环境的稳定。BRM通过调动机体固有能力抵御和消灭肿瘤，成为当
今治疗肿瘤的新模式。随着细胞工程和基因工程的进展，BRM在肿瘤治疗领域大有用武之地。
Biological response modifiers (biological response modifier, BPM) is the body's own cells and molecules, the body of the response to internal and external stimuli in the environment. and in vivo environment for the maintenance of stability. BRM through the mobilization of the body inherent ability to resist and eliminate tumor, the treatment of cancer has become the new model. With cell engineering and genetic engineering progress, BRM in the field of cancer treatment can be fully utilized.
细胞因子 白细胞介素(IL)、干扰素(IFN)、 肿瘤坏死因子(TNF)等除能直接杀伤瘤细胞外，并能活化
体内抗癌细胞， 或分泌抗癌效应分子，或维持免疫效应细胞增殖分化功能，可作为PMM的辅助疗法。
细胞因子 白细胞介素(IL)、干扰素(IFN)、 肿瘤坏死因子(TNF)等除能直接杀伤瘤细胞外，并能活化
体内抗癌细胞， 或分泌抗癌效应分子，或维持免疫效应细胞增殖分化功能，可作为PMM的辅助疗法。
Cytokine interleukin (IL), interferon (IFN), Tumor necrosis factor (TNF), in addition to directly kill tumor cells, and can be activated in vivo cancer cells, or secreted molecule anticancer effect, or maintaining immune effector cell proliferation and differentiation of functions, can be used as adjuvant therapy analyzing.
过继转移的免疫细胞 收集、分离癌性腹水中的淋巴细胞，在体外扩增，并诱导出具杀伤活性的淋巴因
子活化杀伤细胞(LAK细胞)，将之注入体内，有杀伤瘤细胞的作用。同时给予IL—2，可提高疗效。Tani[16]
等将淋巴细胞与病人自身恶性间皮瘤细胞混合培养，加以抗CD3单克隆抗体和IL—2激活之， 生成细胞毒性
T细胞(CTL)。激活的CTL对自身恶性间皮瘤细胞有高度细胞毒性作用。作者给2例PMM病人化疗的同时，腹腔
内注射CTL作为辅助疗法，结果腹水消退，瘤块逐渐消失，改善了患者的生存质量。
Adoptive transfer of immune cells collection, separation, ascites carcinoma of lymphocytes in vitro amplification, issued and induced cytotoxic activity of lymphokine-activated killer cells (LAK cells), to be injected into the body. anti-tumor cells. Given IL-2 may improve the outcome. Tani [16] will be the lymphocytes of patients with malignant mesothelioma cells themselves mixed culture, to be anti-CD3 monoclonal antibody and IL-2 activate it, the generation of cytotoxic T cell (CTL). CTL activation of the cell's own malignant mesothelioma cells with high toxicity. Author to analyzing two cases of chemotherapy patients, while intraperitoneal injection of CTL as a complementary therapy, the results ascites dissipated, tumor gradually disappear and improve the patient's quality of life